MC3482
Based on 9 publication(s) in Google Scholar
MC3482 is a specific sirtuin5 (SIRT5) inhibitor.
For research use only. We do not sell to patients.
- Purity: 98.55%
- CAS No.: 2922280-86-0
- Formula: C33H38N4O8
- Molecular Weight:618.68
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) MC3482
More- Adv Sci (Weinh). 2026 Mar;13(14):e18417. [Abstract]
- Cell Death Dis. 2025 Apr 7;16(1):261. [Abstract]
- Inflammation. 2025 Feb 3. [Abstract]
- Heliyon. 2023 Jul 3;9(7):e17765. [Abstract]
- J Neuroimmune Pharmacol. 2024 May 8;19(1):17. [Abstract]
- J Diabetes Complications. 2021 Nov;35(11):108020. [Abstract]
- Exp Ther Med. 2024 May 22;28(1):295. [Abstract]
- bioRxiv. 2024 August 26.
- Research Square Preprint. 2023 Aug 31.
-
WB
-
IF
-
IHC
-
RT-PCR
-
ELISA
Biological Activity
SIRT5[1]
MC3482 inhibits sirtuin5. 50 μM MC3482 inhibits SIRT5 desuccinylating activity without affecting SIRT5 intracellular expression levels. Autophagy and mitophagy increase in SIRT5-silenced cells and in WT cells treated with MC3482 and decrease in SIRT5-overexpressing cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2922280-86-0
-
Appearance Solid
-
Molecular Weight 618.68
-
Formula C33H38N4O8
-
Color White to off-white
-
SMILES
O=C(N[C@H](C(NC1=CC=CC=C1)=O)CCCCNC(CC[C@@H](C(O)=O)NC(OCC2=CC=CC=C2)=O)=O)OCC3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
SIRT5-RAC2 Axis Drives Monocyte-to-Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency. [Abstract]2026 Mar;13(14):e18417. PMID: 41498691
MC3482 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar;13(14):e18417. [Abstract]
Western blot analysis showing decreased RAC2 protein levels and increased global succinylation in RAW264.7 cells (left) with pharmacological SIRT5 inhibition (MC3482) or in Sirt5 −/− monocytes (right) compared to controls.
MC3482 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar;13(14):e18417. [Abstract]
MC3482(5 mg/kg, i.p.)-treated mice compared to vehicle controls, as demonstrated by increased numbers of resting and growing follicles, along with reduced follicular atresia by IF staining.
MC3482 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar;13(14):e18417. [Abstract]
MC3482 (5 mg/kg, i.p.)-treated mice compared to vehicle controls, as demonstrated by increased numbers of resting and growing follicles, along with reduced follicular atresia by IHC staining.
MC3482 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar;13(14):e18417. [Abstract]
qRT–PCR analyses showed marked reductions in TNF-α and IL-1β at both protein and mRNA levels in MC3482 (5 mg/kg, i.p.)-treated ovaries compared with vehicle controls.
MC3482 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Mar;13(14):e18417. [Abstract]
ELISA analyses showed marked reductions in TNF-α and IL-1β at both protein and mRNA levels in MC3482 (5 mg/kg, i.p.)-treated ovaries compared with vehicle controls.
-
Cell Death Dis
SIRT5-mediated BCAT1 desuccinylation and stabilization leads to ferroptosis insensitivity and promotes cell proliferation in glioma. [Abstract]2025 Apr 7;16(1):261. PMID: 40195331 -
Inflammation
Moxibustion Alleviates Inflammation via SIRT5-mediated Post-translational Modification and Macrophage Polarization. [Abstract]2025 Feb 3. PMID: 39899130 -
Heliyon
Role of SIRT5 in the analgesic effectiveness of moxibustion at ST36 in mice with inflammatory pain. [Abstract]2023 Jul 3;9(7):e17765. PMID: 37455963 -
J Neuroimmune Pharmacol
The Sirtuin 5 Inhibitor MC3482 Ameliorates Microglia‑induced Neuroinflammation Following Ischaemic Stroke by Upregulating the Succinylation Level of Annexin-A1. [Abstract]2024 May 8;19(1):17. PMID: 38717643 -
J Diabetes Complications
Circ-Klhl8 overexpression increased the therapeutic effect of EPCs in diabetic wound healing via the miR-212-3p/SIRT5 axis. [Abstract]2021 Nov;35(11):108020. PMID: 34507876 -
Exp Ther Med
Sirtuin 5 alleviates apoptosis and autophagy stimulated by ammonium chloride in bovine mammary epithelial cells. [Abstract]2024 May 22;28(1):295. PMID: 38827477 -
-
Solvent & Solubility
DMSO : 125 mg/mL (202.04 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.17 mg/mL (3.51 mM); Clear solution
This protocol yields a clear solution of ≥ 2.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (21.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6163 mL | 8.0817 mL | 16.1634 mL | 40.4086 mL |
| 5 mM | 0.3233 mL | 1.6163 mL | 3.2327 mL | 8.0817 mL | |
| 10 mM | 0.1616 mL | 0.8082 mL | 1.6163 mL | 4.0409 mL | |
| 15 mM | 0.1078 mL | 0.5388 mL | 1.0776 mL | 2.6939 mL | |
| 20 mM | 0.0808 mL | 0.4041 mL | 0.8082 mL | 2.0204 mL | |
| 25 mM | 0.0647 mL | 0.3233 mL | 0.6465 mL | 1.6163 mL | |
| 30 mM | 0.0539 mL | 0.2694 mL | 0.5388 mL | 1.3470 mL | |
| 40 mM | 0.0404 mL | 0.2020 mL | 0.4041 mL | 1.0102 mL | |
| 50 mM | 0.0323 mL | 0.1616 mL | 0.3233 mL | 0.8082 mL | |
| 60 mM | 0.0269 mL | 0.1347 mL | 0.2694 mL | 0.6735 mL | |
| 80 mM | 0.0202 mL | 0.1010 mL | 0.2020 mL | 0.5051 mL | |
| 100 mM | 0.0162 mL | 0.0808 mL | 0.1616 mL | 0.4041 mL |